v3.26.1
Significant Agreements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Product Liability Contingency [Line Items]    
Agreement description Pursuant to the Second Amendment, the Company and Cipla were each responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”). The Company shared all other development costs with Cipla that were not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis.  
Transaction cost $ 22,000  
Revenue $ 7,806
Cipla Agreement [Member] | Cipla Technologies LLC [Member]    
Product Liability Contingency [Line Items]    
Non-refundable upfront payment received 22,000  
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]    
Product Liability Contingency [Line Items]    
Transaction cost 12,000  
Revenue 0 6,900
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]    
Product Liability Contingency [Line Items]    
Transaction cost 10,000  
Lease Assignment Agreement [Member]    
Product Liability Contingency [Line Items]    
Decrease in right-of-use asset   $ 8,400
Disposal group write-down of carrying value $ 2,600